CSP
CADL icon

Cary Street Partners’s Candel Therapeutics CADL Stock Holding History

Cary Street Partners’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Buy
+43,100
New +$326K 0.01% 701

Other funds holding CADL

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
LF
LifeSteps Financial Claremont, California $215M AUM 27.52% 1-Year Est. Return

Cary Street Partners's CADL Position: Q2 2026 in Review

Cary Street Partners opened a new position in Candel Therapeutics (CADL) in Q2 2026: 43,100 shares worth $444K. The stake represents 0.01% of the portfolio and ranks #701 among its holdings.

6 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Cary Street Partners held 43,100 shares of Candel Therapeutics worth $444K as of Q2 2026.
  • Candel Therapeutics was a new Cary Street Partners position in Q2 2026.
  • Candel Therapeutics made up 0.01% of Cary Street Partners's portfolio in Q2 2026, its #701 holding.
  • 6 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.